Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Postbiotic Bacillus Subtilis DSM32444 Nasal Spray in Healthy Volunteers
NCT05984004Phase 1Completed
- Sponsor
- Huro Biotech
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Live Biotherapeutic Products, Microbial Metabolites
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Bacillus subtilis DSM32444 in rhinosinusitis (2 arms), sponsored by Huro Biotech. Primary endpoint: Safety and tolerability following multiple doses at Day 7. Started Sep 2022; status: completed.
02
Drugs
Bacillus subtilis DSM32444
03
Conditions
rhinosinusitis
Beyond the preview
Go deeper on NCT05984004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984004.